CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report issued on Thursday morning,Benzinga reports. D. Boral Capital currently has a $14.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Stock Performance

NASDAQ CLGN opened at $2.55 on Thursday. The stock’s fifty day moving average is $3.44 and its two-hundred day moving average is $3.93. The firm has a market capitalization of $29.21 million, a P/E ratio of -1.66 and a beta of 1.07. CollPlant Biotechnologies has a fifty-two week low of $2.54 and a fifty-two week high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.08. CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.36 million. As a group, sell-side analysts forecast that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Institutional Trading of CollPlant Biotechnologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in shares of CollPlant Biotechnologies by 110.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after acquiring an additional 4,405 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in CollPlant Biotechnologies in the 4th quarter valued at approximately $38,000. Benjamin Edwards Inc. purchased a new stake in CollPlant Biotechnologies in the third quarter valued at approximately $112,000. Finally, AMH Equity Ltd raised its position in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the period. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.